Abstract
Major tumor suppressor and transcription factor p53 coordinates expression of many genes hence affecting critical cellular functions including cell cycle, senescence, and apoptosis. The NR4A family of orphan receptors (NR4A1-3) belongs to the superfamily of nuclear receptors. They regulate genes involved in proliferation, cell migration, and apoptosis. In this study, we report an identification of NR4A3 as a direct transcriptional target of p53. Using various techniques, we showed that p53 directly bound the promoter of NR4A3 gene and induced its transcription. Functionally, over-expression of NR4A3 attenuated proliferation of cancer cells and promoted apoptosis by augmenting the expression of pro-apoptotic genes, PUMA and Bax. Knockdown of NR4A3 reversed these phenotypes. Importantly, NR4A3 exhibited tumor suppressive functions both in p53-dependent and independent manner. In addition, NR4A3 physically interacted with an anti-apoptotic Bcl-2 protein hence sequestering it from blunting apoptosis. These observations were corroborated by the bioinformatics analysis, which demonstrated a correlation between high levels of NR4A3 expression and better survival of breast and lung cancer patients. Collectively, our studies revealed a novel transcriptional target of p53, NR4A3, which triggers apoptosis and thus likely has a tumor suppressive role in breast and lung cancers.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Differential impact of yeast cell wall products in recovery of porcine intestinal epithelial cell barrier function following Lipopolysaccharide challenge
Porcine Health Management Open Access 17 April 2023
-
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase
Cell Death & Disease Open Access 05 June 2021
-
Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
Cell Death Discovery Open Access 10 October 2020
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout








References
Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, et al. Characterization of novel markers of senescence and their prognostic potential in cancer. Cell death & Dis. 2014;5:e1528.
Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523–6.
Barlev NA, Sayan BS, Candi E, Okorokov AL. The microRNA and p53 families join forces against cancer. Cell Death Differ. 2010;17:373–5.
Feng Z, Zhang C, Wu R, Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol. 2011;3:44–50.
Hermeking H. p53 enters the microRNA world. Cancer Cell. 2007;12:414–8.
Lezina L, Purmessur N, Antonov AV, Ivanova T, Karpova E, Krishan K, et al. miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress. Cell death & Dis. 2013;4:e953.
Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev. 2014;28:1739–51.
Marouco D, Garabadgiu AV, Melino G, Barlev NA. Lysine-specific modifications ofp53: a matter of life and death? Oncotarget. 2013;4:1556–71.
Fedorova OA, Moiseeva TN, Nikiforov AA, Tsimokha AS, Livinskaya VA, Hodson M, et al. Proteomic analysis of the 20S proteasome (PSMA3)-interacting proteins reveals a functional link between the proteasome and mRNA metabolism. Biochem Biophys Res Commun. 2011;416:258–65.
Moiseeva TN, Bottrill A, Melino G, Barlev NA. DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity. Oncotarget. 2013;4:1338–48.
Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat. 2006;27:14–20.
Amelio I, Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem Sci. 2015;40:425–34.
Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 2000;113(Pt 10):1661–70.
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–4.
Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol. 2008;9:702–12.
Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–31.
Innocente SA, Lee JM. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett. 2005;579:1001–7.
Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol. 2004;180:497–504.
Elias A, Wu J, Chen T. Tumor suppressor protein p53 negatively regulates human pregnane X receptor activity. Mol Pharmacol. 2013;83:1229–36.
Iwano S, Shibahara N, Saito T, Kamataki T. Activation of p53 as a causal step for atherosclerosis induced by polycyclic aromatic hydrocarbons. FEBS Lett. 2006;580:890–3.
Yu C, Yap N, Chen D, Cheng S. Modulation of hormone-dependent transcriptional activity of the glucocorticoid receptor by the tumor suppressor p53. Cancer Lett. 1997;116:191–6.
Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH, Cheng S. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun. 1997;239:617–20.
Olefsky JM. Nuclear receptor minireview series. J Biol Chem. 2001;276:36863–4.
Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2001;8:1243–54.
Beard JA, Tenga A, Hills J, Hoyer JD, Cherian MT, Wang YD, et al. The orphan nuclear receptor NR4A2 is part of a p53-microRNA-34 network. Sci Rep. 2016;6:25108.
Zhao BX, Chen HZ, Lei NZ, Li GD, Zhao WX, Zhan YY, et al. p53 mediates the negative regulation of MDM2 by orphan receptor TR3. EMBO J. 2006;25:5703–15.
Lezina L, Aksenova V, Fedorova O, Malikova D, Shuvalov O, Antonov AV, et al. KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget. 2015;6:25843–55.
Szak ST, Mays D, Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol. 2001;21:3375–86.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–25.
Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA. 2002;99:95–100.
Espinosa JM, Verdun RE, Emerson BM. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell. 2003;12:1015–27.
Shibue T, Suzuki S, Okamoto H, Yoshida H, Ohba Y, Takaoka A, et al. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J. 2006;25:4952–62.
Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene. 2008;27(Suppl 1):S71–83.
Green DR, Reed JC. Mitochondria and apoptosis. Sci (New Y, NY). 1998;281:1309–12.
Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes & Dev. 1999;13:1899–911.
Vander Heiden MG, Thompson CB. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol. 1999;1:E209–216.
Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116:527–40.
Kurakula K, Koenis DS, van Tiel CM, de Vries CJ. NR4A nuclear receptors are orphans but not lonesome. Biochim Et Biophys Acta. 2014;1843:2543–55.
Zhivotovsky B, Orrenius S, Brustugun OT, Doskeland SO. Injected cytochrome c induces apoptosis. Nature. 1998;391:449–50.
Deutsch AJA, Rinner B, Pichler M, Prochazka K, Pansy K, Bischof M, et al. NR4A3 suppresses lymphomagenesis through induction of proapoptotic genes. Cancer Res. 2017;77:2375–86.
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.
Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, et al. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death Differ. 2016;23:509–20.
Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene. 2004;23:3541–9.
Yeh CM, Chang LY, Lin SH, Chou JL, Hsieh HY, Zeng LH, et al. Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer. Sci Rep. 2016;6:31690.
Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol. 2010;30:1535–41.
Malewicz M, Kadkhodaei B, Kee N, Volakakis N, Hellman U, Viktorsson K, et al. Essential role for DNA-PK-mediated phosphorylation of NR4A nuclear orphan receptors in DNA double-strand break repair. Genes & Dev. 2011;25:2031–40.
Stark AM, Pfannenschmidt S, Tscheslog H, Maass N, Rosel F, Mehdorn HM, et al. Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation. Neurol Res. 2006;28:787–93.
Gibson LF, Fortney J, Magro G, Ericson SG, Lynch JP, Landreth KS. Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. Breast Cancer Res Treat. 1999;55:107–17.
Lee SO, Li X, Khan S, Safe S. Targeting NR4A1 (TR3) in cancer cells and tumors. Expert Opin Ther Targets. 2011;15:195–206.
Kitagawa H, Ray WJ, Glantschnig H, Nantermet PV, Yu Y, Leu CT, et al. A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. Mol Cell Biol. 2007;27:7486–96.
Gao W, Fu Y, Yu C, Wang S, Zhang Y, Zong C, et al. Elevation of NR4A3 expression and its possible role in modulating insulin expression in the pancreatic beta cell. PLoS ONE. 2014;9:e91462.
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283–98.
Amelio I, Tsvetkov PO, Knight RA, Lisitsa A, Melino G, Antonov AV. SynTarget: an online tool to test the synergetic effect of genes on survival outcome in cancer. Cell Death Differ. 2016;23:912.
Antonov AV. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic Acids Res. 2011;39:W323–327.
Acknowledgements
O.F., A.P. and E.V. carried out chromatin immunoprecipitation, Luciferase assay, quantitative PCR, cell-cycle analysis, colony formation assay, immunofluorescence, wound-healing and real-time cell migration assay and acknowledge the support from RCF grant 18-75-10076. A.D., O.S., N.B. carried out annexin V, co-immunoprecipitation interaction assay and the bioinformatics analysis and acknowledge the support from RFBR grant 18-29-09144. We appreciate Dr Mikhal Maliewitz (MRC Toxicology, Leicester) for a gift of NR4A1 and NR4A2 antibodies.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Fedorova, O., Petukhov, A., Daks, A. et al. Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis. Oncogene 38, 2108–2122 (2019). https://doi.org/10.1038/s41388-018-0566-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-018-0566-8
This article is cited by
-
Differential impact of yeast cell wall products in recovery of porcine intestinal epithelial cell barrier function following Lipopolysaccharide challenge
Porcine Health Management (2023)
-
Matriptase-2/NR4A3 axis switches TGF-β action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis
Oncogene (2022)
-
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase
Cell Death & Disease (2021)
-
Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
Cell Death Discovery (2020)
-
Tamoxifen-loaded PLA/DPPE-PEG lipid-polymeric nanocapsules for inhibiting the growth of estrogen-positive human breast cancer cells through cell cycle arrest
Journal of Nanoparticle Research (2020)